8:39 AM ET
8-K
Regulatory Approval
Vir Biotechnology Regulatory Approval
Vir Biotechnology announced that the FDA has granted Fast Track designation to VIR-5500, a PSMA-targeted T-cell engager being co-developed with Astellas Pharma for the treatment of metastatic castration-resistant prostate cancer. The designation is intended to expedite the development and review of the drug, which is currently in Phase 1 trials with Phase 3 development anticipated to begin in 2027.
- Counterparty
- Astellas Pharma Inc.